Trial | NCT00653172  Report issue

Title

Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia
A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    302
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults
Study Started
Oct 31
2007
Primary Completion
Jun 30
2008
Study Completion
Nov 30
2008
Last Update
Jan 09
2009
Estimate

Drug NXL103

600mg orally twice daily

Drug comparator

comparator twice daily

Drug NXL103

500mg orally twice daily

1 Experimental

NXL103

3 Active Comparator

2 Experimental

NXL103

Criteria 

Inclusion Criteria:

Community acquired pneumonia

Exclusion Criteria:

severe CAP
respiratory infections attributed to sources other than community acquired bacterial infection
concomitant pulmonary disease
history of hypersensitivity to study medication, macrolide or beta lactam antibiotics
No Results Posted